LCTXLineage Cell Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Lineage Cell Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LCTXEsta | $269M#4 | — | 4.4x#2 | 18.5x#2 | 53.2%#2 | -241.4%#5 | -251.6%#2 | -104.3%#2 | — | — | -20.8%#2 | — |
| OCGN | $338M#1 | — | — | 76.6x#3 | 8.8%#3 | -25.9%#2 | -1425.7%#3 | — | — | — | -16.9%#1 | — |
| CMPX | $333M#2 | — | 2.0x#1 | — | -100.0%#4 | -34.7%#3 | — | -40.0%#1 | — | — | -50.0%#3 | — |
| STRO | $275M#3 | — | — | 2.7x#1 | 65.2%#1 | 15.9%#1 | -154.5%#1 | — | — | — | — | — |
| LIMN | $238M#5 | — | 793.1x#3 | — | — | -187.8%#4 | — | -3395.2%#3 | -170.3%#1 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice